Physician profile
Robert L Meade
NPI 1427006436
$1,704.31
in general payments reported to CMS, 2019-2025
25 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.00 · 2024: $50.33 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.01 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.43 | 2025 | |
| Corcept Therapeutics | $137.84 | 2025 | Korlym |
| Intuitive Surgical, INC. | $124.10 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.25 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $86.55 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $68.13 | 2025 | Mounjaro |
| Astellas Pharma US INC | $61.60 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $60.79 | 2025 | Capvaxive, Gardasil 9, Enflonsia |
| Astrazeneca Pharmaceuticals LP | $58.93 | 2025 | Breztri, Airsupra |
| Exact Sciences Corporation | $41.62 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $40.93 | 2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $31.98 | 2025 | Rexulti |
| Harrow Eye, LLC | $29.40 | 2024 | Vevye |
| Daiichi Sankyo INC. | $25.98 | 2025 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $25.27 | 2025 | Zenpep |
| Sanofi-Aventis U.S. LLC | $24.92 | 2025 | |
| Lundbeck LLC | $24.84 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $22.47 | 2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.35 | 2025 | |
| Pfizer INC. | $20.77 | 2025 | |
| Abbott Laboratories | $17.85 | 2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $16.52 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $13.78 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $13.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Meade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.